We only have this paper's title and publication details.
Read it at the sourceCFRT and HFRT with a tumor-bed boost may have similar low LR and toxicity.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: